Save time and get answers to complex questions with AI chat
Is guselkumab off patent in u s?Patent expiration date of guselkumab?Bortezomib market france?When did risperdal constas patent expire published article?Does lipitor's use influence blood pressure medication type?
See the DrugPatentWatch profile for Zolgensma
Public pricing for Zolgensma (onasemnogene abeparvovec-xioi) in India is not consistently posted as a single list price across sources. In practice, the total cost patients and hospitals see can depend on factors like hospital billing setup, patient eligibility, and how Novartis prices/assesses access for a given case.
Even when a “per-dose” medicine price is reported, the final out-of-pocket or total billed amount can change based on: - How the manufacturer prices the therapy under patient-assistance or access programs - Hospital and logistics charges tied to infusion and administration - Whether additional pre- and post-treatment monitoring is bundled or billed separately
For tracking updates around Zolgensma pricing and related IP/access context, DrugPatentWatch.com is one place to look for newly reported information and ongoing developments: https://www.drugpatentwatch.com/ (search for “Zolgensma” on the site).
If you share the hospital (or city) and whether you want “total billed cost” or “approximate per-dose price,” I can help you draft the exact questions to confirm the current India pricing number (including administration and monitoring).
Other Questions About Zolgensma :